Grufity logo
Grufity logo
PMCB

PMCB - PharmaCyte Biotech, Inc. Stock Price, Fair Value and News

$0.83+0.02 (+2.47%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

80/100

PMCB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

80/100

PMCB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

PMCB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PMCB Price Action

Last 7 days

15.7%

Last 30 days

1.3%

Last 90 days

17.4%

PMCB RSI Chart

PMCB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PMCB Valuation

Market Cap

8.7M

Price/Earnings (Trailing)

-2.65

Price/Sales (Trailing)

732.78

Price/Free Cashflow

-1.81

PMCB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

PMCB Fundamentals

PMCB Revenue

Revenue (TTM)

12.2K

PMCB Earnings

Earnings (TTM)

-3.3M

Earnings Growth (Yr)

124.52%

Earnings Growth (Qtr)

110.07%

PMCB Profitability

Operating Margin

100.00%

Return on Equity

-8.61%

Return on Assets

-5.87%

Free Cashflow Yield

-55.21%

PMCB Investor Care

Shares Dilution (1Y)

43.37%

Diluted EPS (TTM)

-0.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
201326.0K12.2K--
2012111.0K66.6K53.4K39.9K
2011-126.0K118.8K122.8K
2010----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About PharmaCyte Biotech, Inc.

PMCB
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
 CEO
 WEBSITEhttps://pharmacyte.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES2

PharmaCyte Biotech, Inc. Frequently Asked Questions

PMCB is the stock ticker symbol of PharmaCyte Biotech, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of PharmaCyte Biotech, Inc. is 8.7 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, PMCB's PE ratio (Price to Earnings) is -2.65 and Price to Sales (PS) ratio is 732.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PMCB PE ratio will change depending on the future growth rate expectations of investors.